Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par To Market Generic Imitrex Through Deal With Spectrum

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum and Par believe they will be entitled to 180-day exclusivity on the pending Imitrex injection generic.

You may also be interested in...



Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period

Spectrum/Par say launch of subcutaneous sumatriptan could come as early as Aug. 6, 2008.

Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period

Spectrum/Par say launch of subcutaneous sumatriptan could come as early as Aug. 6, 2008.

Generic Flonase To Launch Immediately

Approval of Roxane’s fluticasone propionate nasal spray had been delayed since November due to GSK citizen petitions.

Related Content

Topics

UsernamePublicRestriction

Register

PS063748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel